Cerevance – CVN766

Cerevance is a drug discovery company advancing treatments for brain diseases. The company’s lead program, Cerevance has 5 compounds under development.. The aim of development for CVN766 is to treat psychiatric disorders including negaive and cognitive symptoms of schizophrenia. Craig Thompson is the current CEO.

Organizations:

Stay Connected
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
Privacy Policy
Terms Of Use
Sitemap

The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of Lifespan Research Institute/Lifespan.io, its directors, officers or employees.

Powered by MMD